Evidence map›Paper›PMID 36306518›Full record

ArticleJMIR public health and surveillance2022

The Use of HIV Pre- and Postexposure Prophylaxis Among a Web-Based Sample of HIV-Negative and Unknown Status Cisgender and Transgender Sexual Minority Men: Cross-sectional Study.

Steven A John, K Marie Sizemore, Ruben H Jimenez, S Scott Jones, Andrew E Petroll, H Jonathon Rendina

Open access · goldAbstract read
In one paragraph

Article in JMIR public health and surveillance, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Steven A JohnHealth Intervention Sciences Group / Center for AIDS Intervention Research, Department of Psychiatry and Behavioral Medicine, Medical College of Wisconsin, Milwaukee, WI, United States.ORCID 0000-0002-1316-3920
K Marie SizemoreDepartment of Psychology, Hunter College of the City University of New York, New York, NY, United States.ORCID 0000-0003-0687-4035
Ruben H JimenezDepartment of Psychology, Hunter College of the City University of New York, New York, NY, United States.ORCID 0000-0001-7741-9174
S Scott JonesDepartment of Psychology, Hunter College of the City University of New York, New York, NY, United States.ORCID 0000-0002-5361-8088
Andrew E PetrollHealth Intervention Sciences Group / Center for AIDS Intervention Research, Department of Psychiatry and Behavioral Medicine, Medical College of Wisconsin, Milwaukee, WI, United States.ORCID 0000-0003-3324-1452
H Jonathon RendinaDepartment of Psychology, Hunter College of the City University of New York, New York, NY, United States.ORCID 0000-0002-0148-2852
City University of New York · USMedical College of Wisconsin · US

Funding

Scientific Core (ETR)U19HD089875 · NICHD · WAYNE STATE UNIVERSITY · PI NAAR, SYLVIE · 2016 to 2021
$21.4M
Intervention to reduce drug use and HIV incidence among high PrEP priority partnered YMSMR01DA045613 · NIDA · HUNTER COLLEGE · PI STARKS, TYREL J · 2017 to 2021
$4.9M
Examining Modifiable Psychosocial Predictors of HIV Seroconversion in a Large Nationwide Cohort of High Risk MenUH3AI133674 · NIAID · WHITMAN-WALKER INSTITUTE, INC. · PI RENDINA, H. JONATHON · 2019 to 2021
$3.9M
Testing a Biopsychosocial Model of Minority Stress and Health for HIV-Positive MenR01MH114735 · NIMH · WHITMAN-WALKER INSTITUTE, INC. · PI RENDINA, H. JONATHON · 2017 to 2021
$3.8M
Examining Modifiable Psychosocial Predictors of HIV Seroconversion in a Large Nationwide Cohort of High Risk MenUG3AI133674 · NIAID · HUNTER COLLEGE · PI RENDINA, H. JONATHON · 2017 to 2019
$3.2M
Examining community-based effectiveness of a substance use and HIV risk reduction intervention for young men of colorR01DA041262 · NIDA · HUNTER COLLEGE · PI STARKS, TYREL J · 2016 to 2019
$2.6M
Couples-based intervention to reduce drug use and HIV transmissionR34DA043422 · NIDA · HUNTER COLLEGE · PI STARKS, TYREL J · 2017 to 2019
$667k
Optimizing an IMB-guided intervention to support HIV self-testing and PrEP uptake among YMSM: A pilot factorial RCTK01MH118939 · NIMH · MEDICAL COLLEGE OF WISCONSIN · PI JOHN, STEVEN A · 2019 to 2023
$630k
NIAID NIH HHS UG3 AI133674NIAID NIH HHS UH3 AI133674NICHD NIH HHS U19 HD089875NIDA NIH HHS R01 DA041262NIDA NIH HHS R01 DA045613NIDA NIH HHS R34 DA043422NIMH NIH HHS K01 MH118939NIMH NIH HHS R01 MH114735
6 · The paper itself

Abstract

backgroundHIV disproportionately affects sexual minority men (SMM) in the United States.

objectiveWe sought to determine past HIV postexposure prophylaxis (PEP) use and current and prior pre-exposure prophylaxis (PrEP) use among a web-based sample of cisgender and transgender men who have sex with men.

methodsIn 2019, HIV-negative and unknown status SMM (n=63,015) were recruited via geosocial networking apps, social media, and other web-based venues to participate in a brief eligibility screening survey. Individuals were asked about past PEP use and current and prior PrEP use. We examined associations of demographics, socioeconomic indicators, and recent club drug use with PEP and PrEP use, as well as the association between past PEP use and current and prior PrEP use using generalized linear models and multinomial logistic regression. Statistical significance was considered at P<.001, given the large sample size; 99.9% CIs are reported.

resultsPrior PEP use was reported by 11.28% (7108/63,015) of the participants, with current or prior PrEP use reported by 21.95% (13,832/63,015) and 8.12% (5118/63,015), respectively. Nearly half (3268/7108, 46%) of the past PEP users were current PrEP users, and another 39.9% (2836/7108) of the participants who reported past PEP use also reported prior PrEP use. In multivariable analysis, past PEP use was associated with current (relative risk ratio [RRR] 23.53, 99.9% CI 14.03-39.46) and prior PrEP use (RRR 52.14, 99.9% CI 29.39-92.50). Compared with White men, Black men had higher prevalence of past PEP use and current PrEP use, Latino men had higher prevalence of PEP use but no significant difference in PrEP use, and those identifying as another race or ethnicity reported higher prevalence of past PEP use and lower current PrEP use. Past PEP use and current PrEP use were highest in the Northeast, with participants in the Midwest and South reporting significantly lower PEP and PrEP use. A significant interaction of Black race by past PEP use with current PrEP use was found (RRR 0.57, 99.9% CI 0.37-0.87), indicating that Black men who previously used PEP were less likely to report current PrEP use. Participants who reported recent club drug use were significantly more likely to report past PEP use and current or prior PrEP use than those without recent club drug use.

conclusionsPrEP use continues to be the predominant HIV prevention strategy for SMM compared with PEP use. Higher rates of past PEP use and current PrEP use among Black SMM are noteworthy, given the disproportionate burden of HIV. Nonetheless, understanding why Black men who previously used PEP are less likely to report current PrEP use is an important avenue for future research.

Indexed as

HIV InfectionsIllicit DrugsPre-Exposure ProphylaxisSexual and Gender MinoritiesTransgender PersonsCross-Sectional StudiesFemaleHomosexuality, MaleHumansInternetMaleIllicit DrugsHIVmen who have sex with menpostexposure prophylaxispre-exposure prophylaxissexual minority men

Identifiers

PMID36306518
PMCPMC9804091
OpenAlexW4307844553

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.